Upfront Chromatography A/s

Dpx Holdings B.v.

Duynie Holding B.v.

Other

Upfront Chromatography

Lihme Protein Solutions Aps

Marie Bendix Hansen

Allan Otto Fog Lihme

Morten Aae Olander

Allan Otto Lihme

Timothy J Hobley

Owen R T Thomas

Bodil Ingrid Kjaer Lindved

Martin Pontoppidan

Jurgen Hubbuch

Inga Vaarst Andersen

Brian A Larsen

Rene Oehlenschlaeger Holte

Malene Fog Lihme

Brian Larsen

René Oehlenschlaeger Holte

Inga Vaarts Andersen

The present invention in its broadest aspect relates to a method for reducing glycoalkaloid content and turbidity of an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PT, LipO and PPO; a) providing an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PT, LipO and PPO; and b) performing one or more steps to reduce the concentration of solanine in the dry matter of the aqueous phase with at least 15 percent, such as at least 20%, such as at least 25% and to achieve an optical density at 620 nm of the remaining aqueous phase of less than 0.7; such as less than 0.5; such as less than 0.3; such as less than 0.2; such as less than 0.1; and thereby obtaining an aqueous phase having reduced glycoalkaloid content and turbidity compared to an untreated aqueous phase.

Methods for isolating compounds

The present invention relates to method for purifying proteins using silicates.

Method for purifying proteins using silicate

The present invention in its broadest aspect relates to a method for reducing glycoalkaloid content and turbidity of an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; a) providing an aqueous phase comprising compounds selected from two or more of PA, PI, PPO, LipO, pectin, lipid, glycoalkaloid and phenolic compounds of which at least one compound is selected from PA, PI, LipO and PPO; and b) performing one or more steps to reduce the concentration of solanine in the dry matter of the aqueous phase with at least 15 percent, such as at least 20% such as at least 25% and to achieve an optical density at 620 nm of the remaining aqueous phase of less than 0.7; such as less than 0.5; such as less than 0.3; such as less than 0.2 such as less than 0.1 and thereby obtaining an aqueous phase having reduced glycoalkaloid content and turbidity compared to an untreated aqueous phase.

The invention provides a process for the separation of pea protein. The process begins with an aqueous extract or solution of pea protein, which is passed through at least one expanded bed absorption (EBA) process. The EBA process comprises contacting the aqueous extract or solution of pea protein with at least one adsorbent resin, said adsorbent resin comprising at least one ligand (L1 or L2), having particular chemical structures. Proteins of interest are isolated by eluting them from said adsorbent resin. The invention also provides various protein compositions obtainable via the method of the invention.

Separation processes for pea protein

The invention provides a process for the separation of soy protein. The process begins with an aqueous extract or solution of soy protein, which is passed through at least one expanded bed absorption (EBA) process. The EBA process comprises contacting the aqueous extract or solution of soy protein with at least one adsorbent resin, said adsorbent resin comprising at least one ligand (L1 or L2), having particular chemical structures. Proteins of interest (e.g. trypsin inhibitor (TI) protein or beta-conglycinin) are isolated by eluting them from said adsorbent resin. The invention also provides various novel protein compositions obtainable via the method of the invention.

Separation processes for soy protein

The present invention relates to a method for producing beads comprising a material capable of gelation, said method comprising the steps of: (i) combining (a) a liquid composition comprising a material capable of gelation; and (b) a first hydrophobic phase; (ii) subjecting the liquid composition and the first hydrophobic phase, to means for emulsification in a first reactor by addition of external mechanical energy creating an emulsion comprising individual droplets comprising the material capable of gelation in the first hydrophobic phase (wherein the material capable of gelation provides a discontinuous phase and the first hydrophobic phase provides a continuous phase); (iii) stabilizing the droplets by transferring the emulsion from the first reactor to a stabilization reactor wherein the emulsion obtained in step (ii) is subjected to means for gelation in order to obtain gelation within 5 minutes or less, and the beads are formed.

System and method for producing beads

The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a &#x3b2;-lactoglobulin product and the isolation of an &#x3b1;-enriched whey protein isolate from whey obtained from an animal. The &#x3b1;-enriched whey protein isolate provided by the present invention is besides from being low in &#x3b2;-lactoglobulin also high in &#x3b1;-lactalbumin and immunoglobulin G.

Method for providing a &#x3b2;-lactoglobulin product and an &#x3b1;-enriched whey protein isolate

Thus, a primary aspect of the present invention relates to a method for the fractionation of a protein-containing mixture wherein the protein-containing mixture is selected from the group consisting of milk, milk derived products, milk derived raw materials, vegetable derived products, vegetable derived extracts, fruit derived products, fruit derived extracts, fish derived products, and fish derived extracts, said method comprising the steps of: a) optionally adjusting the pH of the mixture; b) applying said mixture to an adsorption column comprising an adsorbent, said adsorbent comprises a particle with at least one high density non-porous core, surrounded by a porous material, the adsorbent having a particle density of at least 1.5 g/ml and a mean particle size of at most 150 &#x3bc;m; c) optionally washing the column; d) eluting at least one protein from the adsorbent.

Fractionation of protein containing mixtures

Thus, a primary aspect of the present invention relates to a method for the fractionation of a protein-containing mixture wherein the protein-containing mixture is selected from the group consisting of milk, milk derived products, milk derived raw materials, vegetable derived products, vegetable derived extracts, fruit derived products, fruit derived extracts, fish derived products, and fish derived extracts, the method comprising the steps of: a) optionally adjusting the pH of the mixture; b) applying the mixture to an adsorption column comprising an adsorbent, the adsorbent comprises a particle with at least one high density non-porous core, surrounded by a porous material, the adsorbent having a particle density of at least 1.5 g/ml and a mean particle size of at most 150 &#x3bc;m; c) optionally washing the column; d) eluting at least one protein from the adsorbent.

The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts, in the binding process and preferably also the use of small amounts of organic solvents in the elution process. The solid phase matrices, preferably epichlorohydrin activated agarose matrices, are functionalised with mono- or bicyclic aromatic or heteroaromatic ligands (molecular weight: at the most 500 Dalton) which, preferably, comprises an acidic substituent, e.g. a carboxylic acid. The matrices utilised show excellent properties in a 'Standard Immunoglobulin Binding Test' and in a 'Monoclonal Antibody Array Binding Test' with respect to binding efficiency and purity, and are stable in 1M NaOH.

Isolation of immunoglobulins

The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts, in the binding process and preferably also the use of small amounts of organic solvents in the elution process. The solid phase matrices, preferably epichlorohydrin activated agarose matricees, are functionalised with mono- or bicyclic aromatic or heteroaromatic ligands (molecular weight: at the most 500 Dalton) which, preferably, comprises an acidic substituent, e.g. a carboxylic acid. The matrices utilised show excellent properties in a 'Standard Immunoglobulin Binding Test' and in a 'Monoclonal Antibody Array Binding Test' with respect to binding efficiency and purity, and are stable in 1M NaOH.

Isolation of proteins

The invention relates to a method of distributing a liquid in the fluid bed of an up-flow or a down-flow fluid bed reactor. The invention provides efficient distribution and plug flow like fluid flow through the fluid bed where turbulence and/or back-mixing of the fluid are minimized. In accordance with the invention a fluid bed system for use in treating a fluid by contacting the fluid with a solid phase media is provided and the system includes a reactor chamber adapted to contain the solid phase media and at least one fluid distribution means adapted to distribute and/or deliver the fluid to be treated among the particles of the medium.

Bed adsorption system

The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts, in the binding process and preferably also the use of small amounts of organic solvents in the elution process. The solid phase matrices, preferably epichlorohydrin activiated agarose matricees, are functionalised with mono- or bicyclic aromatic or heteroaromatic ligands (molecular weight: at the most 500 Dalton) which, preferably, comprises an acidic substituent, e.g. a carboxylic acid. The matrices utilised show excellent properties in a 'Standard Immunoglobulin Binding Test' and in a 'Monoclonal Antibody Array Binding Test' with respect to binding efficiency and purity, and are stable in 1M NaOH.

Growing community of inventors

Frederiksberg, Denmark

Marie Bendix Hansen